Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Announces Preclinical Findings With IMGN289 Product Candidate For Treatment Of EGFR-Overexpressing Cancers


Wednesday, 10 Apr 2013 08:00am EDT 

ImmunoGen Inc announced preclinical data for EGFR-targeting ADC, IMGN289. The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2013 in Washington, DC (abstracts# 5463, 5467, and 5483). ImmunoGen developed IMGN289 to treat EGFR-overexpressing cancers, which include many cases of squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC), and expects to begin clinical testing of the compound later this year. IMGN289 contains an EGFR-binding antibody that can achieve inhibition of EGFR-signaling, an important mechanism of action for EGFR-overexpressing cancers being fueled by EGFR. In studies reported, the antibody in IMGN289 was shown to provide potency comparable to or better than cetuximab (Erbitux) in preclinical models of SCCHN and NSCLC. The DM1 enables IMGN289 to kill EGFR-overexpressing cancers by a second method that is independent of the sensitivity of these cells to EGFR inhibition. In preclinical models of EGFR-overexpressing cancers reported, IMGN289 was active against NSCLC not dependent on EGFR signaling and against NSCLC with acquired resistance to TKIs; in SCCHN models responsive to EGFR, IMGN289 was significantly more active than cetuximab. 

Company Quote

6.11
-4.74 -43.69%
19 Dec 2014